EBR SYSTEMS INC (EBR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBR

EBR - EBR SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.17
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.01

26 Mar
2025

0.040

OPEN

$1.95

2.03%

HIGH

$2.08

937,540

LOW

$1.91

TARGET
$2.225 10.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
EBR: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 17.8 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 20202021202220232024
EPS Basic xxxxxxxxxxxx-19.0
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxx10.6
Net Operating Cash Flow xxxxxxxxxxxx-62.5 M
Net Profit Margin xxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20202021202220232024
Return on Capital Employed xxxxxxxxxxxx-145.79 %
Return on Invested Capital xxxxxxxxxxxx-58.53 %
Return on Assets xxxxxxxxxxxx-52.77 %
Return on Equity xxxxxxxxxxxx-145.79 %
Return on Total Capital xxxxxxxxxxxx-54.63 %
Free Cash Flow ex dividends xxxxxxxxxxxx-62.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20202021202220232024
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx66 M
Total Debt xxxxxxxxxxxx67 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx98 M
Price To Book Value xxxxxxxxxxxx9.67

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20202021202220232024
Capex xxxxxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx57 M
Research & Development xxxxxxxxxxxx41 M
Investments - Total xxxxxxxxxxxx9 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

31/10/2024

1

Speculative Buy

$1.76

-12.44%

Morgans notes EBR Systems completed a $50m capital raising at 82c per share which is expected to boost investment in commercialisation and manufacturing for WiSE CRT systems ahead of FDA approval in 1Q2025.

Speculative Buy rated. Target price $1.76.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -18.39 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

19/03/2025

1

Overweight

$3.50

74.13%

Wilsons raised both initial and long-term average selling price assumptions for EBR Systems' WiSE-CRT system.

The initial pricing estimate is US$45,000, up US$10,000 from the company's IPO estimate, and the long-term pricing forecast is doubled to US$30,000.

The broker's confidence comes from SOLVE-CRT (which evaluates WiSE's safety) clearing the FDA's trial and pre-approval inspections.

Target price is lifted to $3.50 from $1.62, reflecting an anticipation of FDA approval and a rise in selling price forecasts.

The broker estimates an un-risked price of up to $8.50. Overweight.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -18.85 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -20.99 cents.
Access Extra Coverage Research History >

EBR STOCK CHART

FNArena News on EBR

1
Australian Broker Call *Extra* Edition – Mar 19, 2025

Mar 19 2025 - Daily Market Reports
2
In Brief: Top Picks In Financials, Retail & Healthcare

Mar 07 2025 - Weekly Reports
3
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View
4
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View
5
Rudi’s View: Cochlear, Guzman y Gomez, SiteMinder, Wesfarmers & Xero

Jan 30 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps